title: Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.
authors: L C
authors: LC
authors: Zepeda-Romero
authors: J A
authors: JA
authors: Liera-Garcia
authors: J A
authors: JA
authors: Gutiérrez-Padilla
authors: C I
authors: CI
authors: Valtierra-Santiago
authors: C D
authors: CD
authors: Avila-Gómez
authors: L J
authors: LJ
authors: Cardenas-Lamas
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005355:Fibrosis; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D012163:Retinal Detachment / Q000209:etiology / Q000601:surgery; D012171:Retinal Vessels / Q000473:pathology*; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab